Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic developments for Duchenne muscular dystrophy
Ingrid E.C. Verhaart, Annemieke Aartsma‐Rus
Nature Reviews Neurology (2019) Vol. 15, Iss. 7, pp. 373-386
Closed Access | Times Cited: 334

Showing 1-25 of 334 citing articles:

Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects
Hongyi Li, Yang Yang, Weiqi Hong, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 1379
Duchenne muscular dystrophy
Dongsheng Duan, Nathalie Goemans, Shin’ichi Takeda, et al.
Nature Reviews Disease Primers (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 819
Golodirsen: First Approval
Young‐A Heo
Drugs (2020) Vol. 80, Iss. 3, pp. 329-333
Closed Access | Times Cited: 264
A Highly Sensitive CRISPR‐Empowered Surface Plasmon Resonance Sensor for Diagnosis of Inherited Diseases with Femtomolar‐Level Real‐Time Quantification
Fei Zheng, Zhi Chen, Jingfeng Li, et al.
Advanced Science (2022) Vol. 9, Iss. 14
Open Access | Times Cited: 231
Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping
Paula R. Clemens, Vamshi K. Rao, Anne M. Connolly, et al.
JAMA Neurology (2020) Vol. 77, Iss. 8, pp. 982-982
Open Access | Times Cited: 215
Casimersen: First Approval
Matt Shirley
Drugs (2021) Vol. 81, Iss. 7, pp. 875-879
Closed Access | Times Cited: 210
Viltolarsen: First Approval
Sohita Dhillon
Drugs (2020) Vol. 80, Iss. 10, pp. 1027-1031
Closed Access | Times Cited: 169
Triboelectric Nanogenerators for Therapeutic Electrical Stimulation
Giorgio Conta, Alberto Libanori, Trinny Tat, et al.
Advanced Materials (2021) Vol. 33, Iss. 26
Closed Access | Times Cited: 168
In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges
Matthew Behr, Jing Zhou, Bing Xu, et al.
Acta Pharmaceutica Sinica B (2021) Vol. 11, Iss. 8, pp. 2150-2171
Open Access | Times Cited: 153
Gene Therapy for Duchenne Muscular Dystrophy
Nertiyan Elangkovan, George Dickson
Journal of Neuromuscular Diseases (2021) Vol. 8, Iss. s2, pp. S303-S316
Open Access | Times Cited: 147
Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy
Michela Guglieri, Kate Bushby, Michael McDermott, et al.
JAMA (2022) Vol. 327, Iss. 15, pp. 1456-1456
Open Access | Times Cited: 85
Therapeutic Strategies for Duchenne Muscular Dystrophy: An Update
Chengmei Sun, Luoan Shen, Zheng Zhang, et al.
Genes (2020) Vol. 11, Iss. 8, pp. 837-837
Open Access | Times Cited: 135
High-Capacity Adenoviral Vectors: Expanding the Scope of Gene Therapy
Ana Ricobaraza, Manuela González-Aparicio, Lucia Mora-Jimenez, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 10, pp. 3643-3643
Open Access | Times Cited: 120
The ubiquitin–proteasome system in regulation of the skeletal muscle homeostasis and atrophy: from basic science to disorders
Yasuo Kitajima, Kiyoshi Yoshioka, Naoki Suzuki
The Journal of Physiological Sciences (2020) Vol. 70, Iss. 1
Open Access | Times Cited: 117
Biomarkers for Duchenne muscular dystrophy: myonecrosis, inflammation and oxidative stress
Miranda D. Grounds, Jessica R. Terrill, Basma A. Al-Mshhdani, et al.
Disease Models & Mechanisms (2020) Vol. 13, Iss. 2
Open Access | Times Cited: 104
Impact of Melatonin on Skeletal Muscle and Exercise
Alessandra Stacchiotti, Gaia Favero, Luigi Fabrizio Rodella
Cells (2020) Vol. 9, Iss. 2, pp. 288-288
Open Access | Times Cited: 85
Antisense Drugs Make Sense for Neurological Diseases
C. Frank Bennett, Holly Kordasiewicz, Don W. Cleveland
The Annual Review of Pharmacology and Toxicology (2020) Vol. 61, Iss. 1, pp. 831-852
Open Access | Times Cited: 83
Natural products, PGC-1 , and Duchenne muscular dystrophy
İpek Süntar, Antoni Sureda, Tarun Belwal, et al.
Acta Pharmaceutica Sinica B (2020) Vol. 10, Iss. 5, pp. 734-745
Open Access | Times Cited: 78
Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases
Kathleen L. Miller, Lewis J. Fermaglich, Janet W. Maynard
Orphanet Journal of Rare Diseases (2021) Vol. 16, Iss. 1
Open Access | Times Cited: 67
CRISPR Modeling and Correction of Cardiovascular Disease
Ning Liu, Eric N. Olson
Circulation Research (2022) Vol. 130, Iss. 12, pp. 1827-1850
Open Access | Times Cited: 63
First Regulatory Qualification of a Novel Digital Endpoint in Duchenne Muscular Dystrophy: A Multi-Stakeholder Perspective on the Impact for Patients and for Drug Development in Neuromuscular Diseases
Laurent Servais, Eric Camino, Aude Clement, et al.
Digital Biomarkers (2021) Vol. 5, Iss. 2, pp. 183-190
Open Access | Times Cited: 58
Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders
Sibylle Jablonka, Luisa Hennlein, Michael Sendtner
Neurological Research and Practice (2022) Vol. 4, Iss. 1
Open Access | Times Cited: 51
Autophagy in muscle regeneration: potential therapies for myopathies
Wei Chen, Yushi Chen, Yuxi Liu, et al.
Journal of Cachexia Sarcopenia and Muscle (2022) Vol. 13, Iss. 3, pp. 1673-1685
Open Access | Times Cited: 50
Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy
Paula R. Clemens, Vamshi K. Rao, Anne M. Connolly, et al.
Journal of Neuromuscular Diseases (2022) Vol. 9, Iss. 4, pp. 493-501
Open Access | Times Cited: 46
Semirational bioengineering of AAV vectors with increased potency and specificity for systemic gene therapy of muscle disorders
Jihad El Andari, Edith Renaud-Gabardos, Warut Tulalamba, et al.
Science Advances (2022) Vol. 8, Iss. 38
Open Access | Times Cited: 46
Page 1 - Next Page

Scroll to top